Translational research in Cancer and other prevalent chronic diseases
Lines of Research
01.Evaluation of Health Services in oncological diseases
02.Study of Biomarkers of Immunoediting and Response to Immunotherapy in cancer, and health outcomes attributable to said immunotherapy.
03.Estudio de Biomarcadores de Inmunoedición y de Respuesta a la Inmunoterapia en cáncer, y resultados en salud atribuibles a dicha inmunoterapia.
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
TransBioLine
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
ABSTRACT
Partners
-
-
- UNIVERSITAT ZURICH (Coordinator)
- UNIVERSIDAD DE MALAGA
- INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA
- LANDSPITALI UNIVERSITY HOSPITAL
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
- THE UNIVERSITY OF NOTTINGHAM
- UNIVERSIDAD DE SALAMANCA
- FUNDACIO PRIVADA INSTITUT DE RECERCA DE L’HOSPITAL DE LA SANTA CREU I SANT PAU TAMIRNA GMBH
- SIGNATOPE GMBH
- ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH
- METAHEPS GMBH
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
- SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
-
-
-
- CHARITE – UNIVERSITAETSMEDIZIN BERLIN
- UNIVERSITY OF NEWCASTLE UPON TYNE
- THE UNIVERSITY OF LIVERPOOL
- MLM MEDICAL LABS GMBH
- UNIVERSITEIT LEIDEN
- SERVICIO ANDALUZ DE SALUD
- PFIZER LIMITED
- MERCK SHARP & DOHME CORP
- Eli Lilly and Company Limited
- NOVARTIS PHARMA AG
- HOFFMANN-LA ROCHE AG
- JANSSEN PHARMACEUTICA NV
- SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
-
ASSERT
Development of a nanotechnology-based innovative assay for the diagnosis of allergy to Betalactams
ABSTRACT
Betalactams (BL) are the most widely used antibiotics and the first-choice drugs to control several bacterial infections, however, they can lead to serious allergic reactions in up to 10% of the general population. The current diagnosis of allergy to BL includes skin test and/or drug provocation tests, which are invasive and carry a risk of anaphylaxis requiring hospitalisation. Basophil activation test (BAT) is one of the best options for diagnosis of allergy because it is free of risk and at a reduced cost for health care. The ASSERT project will bring a nanotechnology-based BAT assay specific for allergy to BL with higher sensitivity and specificity, which are the main weakness of the current assays. Of importance, the number and conformation of displayed antigens at the nanoparticle surface will be controlled to assure standardisation and increase precision and reproducibility of the assay. In addition, a complete validation plan is envisaged to fit the standards for clinical diagnostics. The two factors for the success of the project are, one one hand, the solid experience of the host lab in immunology, specially allergy and nanoparticle technology and, on the other hand, the expertise of the candidate in
immunology, molecular biology and test validation design for clinical diagnostics. Moreover, the the two way of transfer of knowledge is assured, which will help the candidate to restart her research career in the European Union. Finally, the expected results of the project will contribute to enlarge the basic knowledge about allergen-specific activation of basophils, and will give rise to an optimised BL-BAT assay with the required clinical and analytical validation to be used in diagnostics.
Communication Actions
Participation of Dr Cecilia Frecha in European Researchers’ Night 2023
🔬 On September 29th 2023, Dr. Cecilia Frecha, showcased their groundbreaking research at ‘The European Researchers’ Night’ in Málaga using gamification techniques to make biomedical science engaging for everyone. 🎮
Check how it was clicking on any of our social media profiles
ECRAID-Base
European Clinical Research Alliance on Infectious Disease
ABSTRACT
Partners
-
-
- UNIVERSITEIT ANTWERPEN
- UNIVERSITAIR ZIEKENHUIS ANTWERPEN
- ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
- Centre hospitalier universitaire de Limoges
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- FONDAZIONE PENTA ETS
- UNIVERSITE DE GENEVE
- UNIVERSITATSKLINIKUM HEIDELBERG
- STICHTING AMSTERDAM UMC
- SERVICIO ANDALUZ DE SALUD
-
-
-
- FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
- UNIVERSITA DEGLI STUDI DI VERONA
- KLINIKUM DER UNIVERSITAET ZU KOELN
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
- INTENSIVE CARE NATIONAL AUDIT AND RESEARCH CENTRE
- KLINIKA ZA INFEKTIVNE BOLESTI DR. FRAN MIHALJEVIC
- EUROPEAN SOCIETY CLINICAL MICROBIOLOGY INFECTIOUS DISEASES (EUROPAISCHE GESELLSCHAFT
- FUR KLINISCHE MIKROBIOLOGIE INFEKTIONSKRANKHEITEN
- EUROPEAN RESPIRATORY SOCIETY
-
ORTHO-ALLO-UNION
ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non-union
ABSTRACT
Partners
-
-
- SERMAS SERVICIO MADRILENO DE SALUD
- UULM UNIVERSITAET ULM
- POLICLINICO FONDAZIONE IRCCS CA’ GRANDA – OSPEDALE MAGGIORE POLICLINICO
- EFS ETABLISSEMENT FRANCAIS DU SANG
- UNIMORE UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
- INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
- UAM UNIVERSIDAD AUTONOMA DE MADRID
- APHP ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
-
STOP IATRO
Start Therapeutic OPtimisazion and IATRogenesis prevention on Older People
ABSTRACT
Partners
-
-
- Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Centre Hospitalier Universitaire de Limoges (CHU Limoges)
- Fundació Salut i Envelliment de la Universitat Autònoma de Barcelona (FSiE UAB Foundation)
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA-FIMABIS)
- University of Aveiro (Universidade de Aveiro)
-
INTERACT-EUROPE 100
ABSTRACT
The INTERACT-EUROPE100 project aims at implementing the Inter-specialty Cancer Training (ISCT) curriculum developed under the INTERACT-EUROPE project. The objective of the ISCT programme isto foster a patient-centric approach to quality cancer care through the promotion of multidisciplinary and multi-professional teams working across Europe. The project will critically review the current state of inter-specialty training resources, identify existing quality learning materials and produce innovative learning resources to meet the requirements of the ISCT curriculum and ensure the needs of oncology patients across Europe are addressed. In the framework of the project, two new modules focusing on paediatric oncology and the specific needs of Ukrainian displaced healthcare professionals and people in care will be developed. A dedicated digital learning management system adapted to the needs of oncology professionals will be established to support the decentralised implementation of the ISCT programme for trainers and trainees at the national level. The activities linked to the training of trainers will target experts in the fields of clinical oncology, surgery, radiation oncology, cancer nursing and other specialised staff from at least 100 cancer centres in Europe and will ensure the future sustainability of the ISCT programme in EU Members States. Local and international events for trainers will facilitate the exchange of best learning practices and establish an EU network of inter-specialty cancer trainers to achieve best patient outcomes.
Partners
-
-
- UNIVERSITA DEGLI STUDI DELL’AQUILA (UNIVAQ)
- AKADEMIA GORNICZO-HUTNICZA IM. STANISLAWA STASZICA W KRAKOWIE (AGH / AGH-UST)
- UNIVERSITA CAMPUS BIO MEDICO DI ROMA (UNICAMPUS)
- INSTYTUT CENTRUM ZDROWIA MATKI POLSKI (ICZMP)
- IRCCS SAN RAFFAELE ROMA SRL (HSR)
- SERVICIO ANDALUZ DE SALUD (SAS)
- MEDICAL SERVICES INSTITUTE MSI (MSI)
- POLSKIE STOWARZYSZENIE DIABETYKOW (PDA)
- UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA (UNIROMA1)
-
ProCure
Public Procurement Assessment in the Healthcare Sector
ABSTRACT
Public Procurement Assessment in the Healthcare Sector (ProCure) brings together 25 partners from 13 EU countries: public buyers, central purchasing bodies, regional health agencies, vendors, etc. as well as other organizations involved in public purchases made for hospitals (e.g. supporting organizations, private procurers, etc.) to make a thorough assessment of public procurement practices to manage them more effectively and precisely. ProCure assessment will focus on the impact of pandemic in procurement organizations and practices from the 13 participating MS, but not only. By means of comparison, ProCure will determine what changed in relation to the pre-pandemic scenario and, also, what new strategies, action plans, policies have been incorporated to public procurement as a result of the COVID-19 crisis. The overarching goal is to help leaders gauge and track their state of readiness and identify opportunities for improvement. In addition, this project will broad lessons learnt from previous health crisis to outline new or improved national and regional strategies on public procurement. The final goal will be making current practices more resilient and efficient all over the European Union, and to ensure that public health systems are ready for whatever crises the future brings. ProCure methodology will follow a step-by-step process:
-
-
- Phase 1-Observational study in which facts and data collected and transformed in information;
- Phase 2- Identification and definition of the stakeholders’ preferences, their needs and expectations (Delphi method) in which information is converted into knowledge following a scientific approach that distances itself from subjectivity.
- Phase 3-Structured dialogue in which the knowledge acquired is the base to determine new strategies for the health procurement systems in order to increase preparedness for future health procurement challenges.
-
Partners
-
-
- UNIVERSITA DEGLI STUDI DELL’AQUILA (UNIVAQ)
- AKADEMIA GORNICZO-HUTNICZA IM. STANISLAWA STASZICA W KRAKOWIE (AGH / AGH-UST)
- UNIVERSITA CAMPUS BIO MEDICO DI ROMA (UNICAMPUS)
- INSTYTUT CENTRUM ZDROWIA MATKI POLSKI (ICZMP)
- IRCCS SAN RAFFAELE ROMA SRL (HSR)
- SERVICIO ANDALUZ DE SALUD (SAS)
- MEDICAL SERVICES INSTITUTE MSI (MSI)
- POLSKIE STOWARZYSZENIE DIABETYKOW (PDA)
- UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA (UNIROMA1)
-
3TR
3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions
ABSTRACT
Partners
-
-
- THE UN IVERSITY OF MANCHESTER
- CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
- UNIVERSITY OF LEICESTER
- EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
- FUNDACIO CENTRE DE REGULACIO GENOMICA
- EUROPEAN RESPIRATORY SOCIETY
- FONDAZIONE IRCCS CA’ GRANDA – OSPEDALE
- MAGGIORE POLICLINICO
- ACADEMISCH MEDISCH CENTRUM BIJ DE
- UNIVERSITEIT VAN AMSTERDAM
- ACADEMISCH ZIEKENHUIS GRONINGEN
- ALACRIS THERANOSTICS GMBH
- ATRYS HEALTH, SA,
- AZIENDA OSPEDALE UNIVERSITA PADOVA
- AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER,
- UNIVERSITEIT GENT
- REGION HOVEDSTADEN
- CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE
- NANCY
- UNIVERSITY OF GLASGOW
- CHARITE – UNIVERSITAETSMEDIZIN BERLIN
- AGENCIA ESTATAL CONSEJO SUPERIOR
- DEINVESTIGACIONES CIENTIFICAS
- CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES
- AUGUST PI I SUNYER
- CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
- Deutsches Rheuma-Forschungszentrum Berlin
- EUROPEAN FEDERATION OF ASTHMA &ALLERGY
- ASSOCIATIONS IDEELL FORENING
- EUROPEAN LUNG FOUNDATION
- GENOS DOO ZA VJESTACENJE I ANALIZU
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND
- MEDICINE
- INSTITUT NATIONAL DE LA SANTE ET DE LA
- RECHERCHE MEDICALE
- INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO
- ANTUNES
- KAROLINSKA INSTITUTET
- LUPUS EUROPE
-
-
-
- PHILIPPS UNIVERSITAET MARBURG
- QUEEN MARY UNIVERSITY OF LONDON
- SERVICIO ANDALUZ DE SALUD
- SERVICIO MADRILENO DE SALUD
- SIP SERVICE S.R.L.
- SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE
- STICHTING VUMC
- TECHNISCHE UNIVERSITAET DRESDEN
- THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
- THE QUEEN’S UNIVERSITY OF BELFAST
- UNIVERSITA DEGLI STUDI DI CATANIA
- UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
- UNIVERSITA DEGLI STUDI DI CAGLIARI
- UNIVERSITA DEGLI STUDI DI GENOVA
- UNIVERSITA DI PISA,
- UNIVERSITAT BASEL
- CLINIQUES UNIVERSITAIRES SAINT-LUC
- UNIVERSITE DE BRETAGNE OCCIDENTALE
- UNIVERSITEIT HASSELT
- UNIVERSITETET I BERGEN
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND DUBLIN
- UNIVERSITY COLLEGE LONDON
- KATHOLIEKE UNIVERSITEIT LEUVEN
- UNIVERSITY OF SOUTHAMPTON
- UNIVERSYTET MEDYCZNY W LODZI.
- VIB VZW
- SANOFI-AVENTIS DEUTSCHLAND GMBH
- JANSSEN PHARMACEUTICA NV
- TAKEDA DEVELOPMENT CENTRE EUROPE LTD
- ASTRAZENECA AB
- GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
- NOVARTIS PHARMA AG
- PFIZER LIMITED
- F. HOFFMANN-LA ROCHE AG
- MEDIZINISCHE HOCHSCHULE HANNOVER
- OREBRO UNIVERSITY
- OWLSTONE MEDICAL LIMITED
-
LIVERATION
Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?
ABSTRACT
Colorectal cancer (CRC) ranks fourth in cancer deaths worldwide. Between 20% and 30% of patients with advanced CRC have liver metastases (CRLM). Liver cancer ranks second in cancer deaths worldwide, including hepatocellular carcinoma (HCC). Despite recent advances, liver resection offers the only chance of cure for patients with liver metastases. However, the recurrence rate of these tumours is high even after post-resection. The presence of positive margins in the remaining liver after resection correlates with increased local recurrence and decreased overall survival, the only factor where prognosis could be influenced by the performance of surgery. However, at present, the extent of an R-negative status remains debatable and varies widely from one publication to another. Currently, there are radiofrequency ablation studies that, based on preliminary retrospective human clinical trials, are able to correlate an additional coagulation of tumor margins with a reduction on local recurrence. However, there is no prospective and pragmatic controlled study that accurately measuresthis additional margin and itsimpact on oncological outcomes. The aim of LIVERATION isto conduct an ambitious, pragmatic multicenter clinical trial with 720 patients with CRLM and HCC at 24 clinical centres in 6 different countries to determine whether additional ablated margin produced by radiofrequency can decrease the recurrence rate and improve patient survival. We will also evaluate the patient-centredness of the intervention and its comparativeness with other therapeutic alternatives in terms of quality of life and patient experience in real-world settings. To this end, the consortium has been formed by highly experienced, highly qualified and multidisciplinary entities to carry out the project successfully. The results will not only have a major impact on a social and scientific level but also on an economic level for the EU. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
Partners
-
-
- IMIM CONSORCIO MAR PARC DE SALUT DE BARCELONA
- VECMEDICAL SPAIN SL
- SOCIEDAD PARA EL AVANCE CIENTIFICO – SOCIETY FOR THE IMPROVEMENT OF SCIENCE
- SHINE 2EUROPE LDA
- EUROPEAN LIVER PATIENTS ASSOCIATION
- FUNDACION AVEDIS DONABEDIAN PARA LA MEJORA DE LA CALIDAD ASISTENCIAL
- PANEPISTIMIO IOANNINON
- ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
-
DIFAMEM
Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic interactions
ABSTRACT
RESULTS
Partners
DrNanoDAll
Nanodiagnosis for Betalactam Hypersensitivity
ABSTRACT
Partners
Webinar sobre el piloto sobre «Blind Evaluations» en HE
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
Lump Sum Funding in Horizon Europe: How does it work?
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
DISSEMINATION & EXPLOITATION IN HORIZON EUROPE
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
GENDER DIMENSION IN HORIZON EUROPE
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
EVALUATION OF INTELLECTUAL PROPERTY MANAGEMENT
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
ETHICAL ASPECTS EVALUATION
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
OPEN SCIENCE EVALUATION
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
RESPONSIBLE RESEARCH AND INNOVATION (RRI), OPEN SCIENCE Y DATA MANAGEMENT
Para no perderte la próxima formación, subscríbete a nuestra Newsletter que encontrarás en el pie de página de la web.
Training on Horizon Europe proposal writing
Curso de formación organizado por el portal europeo Horizon Europe NCP sobre las claves a la hora de escribir propuestas hacia Horizonte Europa realizado en Septiembre de 2021.
A continuación, podrás visionar toda la jornada en el siguiente vídeo, que podrás ver desde esta misma página o dirigirte a Youtube.
Para más información, cursos y material de interés, puede dirigirse a la página oficial de Horizon Europe NCP Portal
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
Maximino Redondo Bautista
-
Co-investigator in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
-
Senior InvestigatorSerán aquellos que tengan una actividad investigadora de al menos 5 años en la etapa posdoctoral. Estos investigadores estarán adscritos a un Grupo de Investigación liderado por un Investigador Responsable. Las funciones serán las que le tenga asignadas su IR.
Pueden liderar una línea de investigación de alguno de los grupos de investigación del Instituto, con financiación competitiva propia, y con potencial para llegar a convertirse responsable de un grupo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Collaborating Healthcare ResearcherSerá Investigador Asistencial Colaborador el Investigador que no reúne la consideración de Investigador Posdoctoral. Estarán adscritos a un Grupo de Investigación liderado por un IR. Las funciones serán las que le tenga asignada su IR.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Postdoctoral and/or junior researchersEsta etapa posdoctoral estará restringida a Investigadores del Instituto que tengan el título doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque aún no hayan establecido un nivel significativo de independencia. Además, pueden tener actividades de docencia y/o asistencial más allá de su trabajo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Predoctoral and/or Training Researchers
Los investigadores predoctorales y/o en formación serán aquellos investigadores que realizan investigaciones bajo supervisión en una línea de investigación orientada a la resolución de problemas de salud. Incluye aquellos investigadores que están cursando un doctorado (incluyendo a los contratados Río Hortega)
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.